ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
暂无分享,去创建一个
J. Brody | Jun Zhu | Yongping Song | T. Heineman | J. Maly | G. Nowakowski | Ling Li | Lei Zhang | F. Lansigan | H. Jing | Stephen D. Smith | Qingyuan Zhang | Junning Cao | S. Rizvi | Yuqin Song | J. Lue | M. Jivani | W. Luo | Xiuhua Sun | J. Sun | I. Han | Young Liu | G. Nowakowski